Publications (40) ADELA SERRANO GIMENO publications

2024

  1. Atrial Fibrillation Prevalence Rates and Its Association with Cardiovascular–Kidney–Metabolic Factors: SIMETAP-AF Study

    Medicina (Lithuania), Vol. 60, Núm. 8

  2. Hyperuricaemia Prevalence Rates According to Their Physiochemical and Epidemiological Diagnostic Criteria and Their Associations with Cardio-Renal-Metabolic Factors: SIMETAP-HU Study

    Journal of Clinical Medicine, Vol. 13, Núm. 16

2023

  1. Elevated pulse pressure and cardiovascular risk associated in Spanish population attended in primary care: IBERICAN study

    Frontiers in Cardiovascular Medicine, Vol. 10

  2. Heart Failure Prevalence Rates and Its Association with Other Cardiovascular Diseases and Chronic Kidney Disease: SIMETAP-HF Study

    Journal of Clinical Medicine, Vol. 12, Núm. 15

  3. Prevalence Rates of Arterial Hypertension According to the Threshold Criteria of 140/90 or 130/80 mmHg and Associated Cardiometabolic and Renal Factors: SIMETAP-HTN Study

    Medicina (Lithuania), Vol. 59, Núm. 10

2022

  1. Case-fatality rates of SARS-CoV-2 infection according to Autonomous Communities during the second epidemic wave in Spain

    Semergen, Vol. 48, Núm. 4, pp. 252-262

  2. Evaluation of prophylaxis in primary prevention with acetylsalicylic acid in people with diabetes: A scoping review

    Semergen, Vol. 48, Núm. 4, pp. 275-292

  3. SEMERGEN positioning on approaching chronic heart failure in primary care

    Semergen, Vol. 48, Núm. 2, pp. 106-123

  4. The natriuretic peptides in the diagnosis of heart failure in primary care setting

    Semergen, Vol. 48, Núm. 7

2021

  1. Analysis of case fatality rate of SARS-CoV-2 infection in the Spanish Autonomous Communities between March and May 2020

    PLoS ONE, Vol. 16, Núm. 12 December 2021

  2. Application of the PCR number of cycle threshold value (Ct) in COVID-19

    Semergen, Vol. 47, Núm. 5, pp. 337-341

  3. COVID-19 vaccine and anticoagulation patients at high cardiovascular risk. SEMERGEN recommendations

    Semergen

  4. GSE4-loaded nanoparticles a potential therapy for lung fibrosis that enhances pneumocyte growth, reduces apoptosis and DNA damage

    FASEB Journal, Vol. 35, Núm. 3

2020

  1. COVID-19. History repeats itself and we keep stumbling on the same stone

    Semergen, Vol. 46, pp. 48-54

2017

  1. Consensus on the Statin of Choice in Patients with Impaired Glucose Metabolism: Results of the DIANA Study

    American Journal of Cardiovascular Drugs, Vol. 17, Núm. 2, pp. 135-142

  2. Enfermedad renal crónica y dislipidemia

    Clinica e Investigacion en Arteriosclerosis

2016

  1. Consenso Delphi sobre el manejo de la dislipidemia en pacientes con alteración del metabolismo de la glucosa: Estudio Diana

    Clinica e Investigacion en Arteriosclerosis, Vol. 28, Núm. 3, pp. 132-140

  2. Delphi consensus on the diagnosis and management of dyslipidaemia in chronic kidney disease patients: A post hoc analysis of the DIANA study

    Nefrologia, Vol. 36, Núm. 6, pp. 679-686

  3. Evaluation of the Ocular Tolerance of Three Tacrolimus Topical Pharmaceutical Preparations by Bovine Corneal Opacity and Permeability Test

    Current Eye Research, Vol. 41, Núm. 7, pp. 890-896

2015

  1. Dietary inflammatory index and incidence of cardiovascular disease in the PREDIMED study

    Nutrients, Vol. 7, Núm. 6, pp. 4124-4138